Mesoblast stock: Consensus cuts 2027 revenue forecast for Mesoblast stock to USD 177.90 million

Published on 10/22/2026 at 20:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Consensus lifts 2027 loss forecast to USD 0.017 per share. Mesoblast stock costs EUR 1.14 on October 22, 2026 at Lang & Schwarz.

Consensus estimates revised

Consensus cut Mesoblast's fiscal 2027 revenue forecast to USD 177.90 million on October 20, 2026.
The fiscal 2027 loss forecast rose to USD 0.017 per share on October 20, 2026.
Mesoblast stock was at EUR 1.14 at Lang & Schwarz on October 22, 2026 at 8:38 p.m. CEST.
Mesoblast's annual meeting is scheduled for November 10, 2026.

MESO, AU000000MSB8, Illustration mit AI erstellt.

Mesoblast's fiscal 2027 revenue forecast was cut to USD 177.90 million on October 20, 2026, while the expected loss widened to USD 0.017 per share. Simply Wall St reported that the revenue forecast fell from USD 186.30 million and the expected loss increased from USD 0.0095 per share. Mesoblast stock was at EUR 1.14 at Lang & Schwarz on October 22, 2026 at 8:38 p.m. CEST.

Forecasts point to slower growth

The revision lowers the expected fiscal 2027 revenue by USD 8.40 million, or 4.51 percent, from the earlier USD 186.30 million estimate. The loss forecast also increased by USD 0.0075 per share, equal to 78.95 percent versus the prior USD 0.0095 estimate.

The change follows a series of estimate updates covering Mesoblast's commercial cell therapy business and development pipeline. The same Simply Wall St update said the consensus price target was USD 3.59 in Australian currency terms, while the estimate revision focused on revenue and earnings assumptions.

Nasdaq range remains wide

On Nasdaq, Mesoblast's American depositary shares last traded at USD 12.52 on October 22, 2026 at 2:44 p.m. ET. The 52-week range was USD 11.89 to USD 21.50, placing the quote USD 0.63, or 5.31 percent, above the low and USD 8.98, or 41.77 percent, below the high. Market capitalization stood at USD 1.6 billion on the same date.

Annual meeting has a fixed date

Mesoblast's annual general meeting is scheduled for November 10, 2026. Simply Wall St lists the meeting as the next dated corporate event. The company's investor page lists the financial year ended June 30, 2026, as its latest reported period, with revenue of USD 120.25 million and a net loss of USD 57.50 million.

That annual result represented revenue growth of USD 103.05 million, or 599.20 percent, from USD 17.20 million in fiscal 2025. Net loss narrowed by USD 44.64 million, or 43.71 percent, from USD 102.14 million in the prior fiscal year.

Price and estimates set the frame

The current estimate revision puts commercial execution and pipeline spending side by side. Revenue of USD 120.25 million in fiscal 2026 provides the latest reported base, while the USD 177.90 million fiscal 2027 forecast implies USD 57.65 million of additional revenue if achieved.

Mesoblast stock stays in focus

The combination of a lower revenue forecast and a wider projected loss gives the November meeting added relevance for shareholders assessing the company's commercial progress and development spending. The latest euro indication remains an intraday quote, while the Nasdaq range shows how far the stock sits from its yearly high.

The further course of trading is shown by the continuously updated real-time quote of Mesoblast stock.